NASDAQ:NBRV Nabriva Therapeutics (NBRV) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free NBRV Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range$0.00▼$0.5252-Week Range N/AVolumeN/AAverage Volume29,344 shsMarket Capitalization$45.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsSocial Media Get Nabriva Therapeutics alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Nabriva Therapeutics Stock (NASDAQ:NBRV)Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Read More Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. NBRV Stock News HeadlinesApril 17, 2024 | americanbankingnews.comNabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated by Analysts at StockNews.comApril 13, 2024 | morningstar.comNabriva Therapeutics PLC NBRVFApril 24, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.July 11, 2023 | finanznachrichten.deArbutus Biopharma Corporation: Arbutus Appoints Two New ExecutivesMay 26, 2023 | finance.yahoo.comNBRV - Nabriva Therapeutics plcFebruary 28, 2023 | marketwatch.comBacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029February 25, 2023 | seekingalpha.comNBRV Nabriva Therapeutics plcJanuary 6, 2023 | finance.yahoo.comNabriva Therapeutics Provides Corporate UpdateApril 24, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… November 28, 2022 | marketwatch.comNabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial DataNovember 28, 2022 | markets.businessinsider.comNabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic FibrosisNovember 28, 2022 | markets.businessinsider.comNabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock UpNovember 28, 2022 | bizjournals.comNabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 28, 2022 | seekingalpha.comNabriva gains after announcing Phase 1 data for cystic fibrosis candidateNovember 28, 2022 | finance.yahoo.comNabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNovember 28, 2022 | finance.yahoo.comNabriva's stock is up after sharing antibiotic newsNovember 28, 2022 | finance.yahoo.comNabriva's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 10, 2022 | finance.yahoo.comMontgomery County biopharmaceutical firm reducing workforce by 40%November 10, 2022 | technews.tmcnet.comNabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateNovember 10, 2022 | finance.yahoo.comNabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateNovember 7, 2022 | finance.yahoo.comNabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022September 15, 2022 | finance.yahoo.comNabriva Therapeutics Announces Date of 1-for-25 Reverse Stock SplitSeptember 14, 2022 | finance.yahoo.comAll You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to BuySeptember 6, 2022 | finance.yahoo.comNabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 12, 2022 | marketwatch.comNabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA(R) (lefamulin) in Adult Patients with Cystic FibrosisAugust 11, 2022 | finance.yahoo.comNabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisAugust 4, 2022 | seekingalpha.comNabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q2 2022 Results - Earnings Call TranscriptSee More Headlines Receive NBRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NBRV CUSIPN/A CIK1641640 Webwww.nabriva.com Phone(531) 649-2000Fax610-816-6639Employees39Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($19.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,190,000.00 Net Margins-148.11% Pretax Margin-144.78% Return on Equity-365.53% Return on Assets-135.81% Debt Debt-to-Equity Ratio0.12 Current Ratio0.85 Quick Ratio0.52 Sales & Book Value Annual Sales$35.59 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / BookN/AMiscellaneous Outstanding Shares32,015,000Free Float31,493,000Market Cap$45.46 million OptionableNot Optionable Beta1.53 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Colin Broom M.D. (Age 67)Director Comp: $40kMr. J. Christopher Naftzger BA (Age 56)Esq., J.D., Interim CEO, Gen. Counsel & Sec. Mr. Daniel Dolan (Age 46)Chief Financial Officer Key CompetitorsAadi BioscienceNASDAQ:AADIRockwell MedicalNASDAQ:RMTIJaguar HealthNASDAQ:JAGXImmuneeringNASDAQ:IMRXCleneNASDAQ:CLNNView All Competitors NBRV Stock Analysis - Frequently Asked Questions How were Nabriva Therapeutics' earnings last quarter? Nabriva Therapeutics plc (NASDAQ:NBRV) posted its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($13.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($16.75) by $3.50. The biotechnology company had revenue of $2.53 million for the quarter, compared to analysts' expectations of $2.25 million. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 365.53% and a negative net margin of 148.11%. Read the conference call transcript. When did Nabriva Therapeutics' stock split? Nabriva Therapeutics's stock reverse split on Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Nabriva Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX). How do I buy shares of Nabriva Therapeutics? Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NBRV) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
